The Mexico blood glucose monitoring devices market size is expected to grow from USD 388.86 million in 2025 to USD 420.25 million in 2026 and is forecast to reach USD 642.59 million by 2031 at 8.86% CAGR over 2026-2031. This report is segmented by Device Type (SMBG Devices: Glucometers, Test Strips, Lancets; CGM Devices: Sensors, Durables), Patient Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), and End-User (Hospitals & Clinics, Homecare Settings, Diagnostic Centers, and Specialty Diabetes Facilities). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
CGM devices are projected to expand at a 9.71% CAGR through 2031, faster than the conventional device category, supporting continued growth in mexico continuous glucose monitoring adoption. Abbott’s 2025 Mexican launch of FreeStyle Libre 2 Plus added real-time alarms and connected functionality to the local CGM offer. These features address needs that intermittent measurement cannot fully meet, especially for patients requiring closer glucose oversight. The category’s expansion is nevertheless limited by the cost of sensors and the absence of broad public reimbursement. CGM is likely to grow first through endocrinology practices and private pharmacies in large cities. The Mexico blood glucose monitoring devices market will thus combine a high-volume SMBG base with a smaller but faster-moving sensor category. Adoption will depend on whether suppliers can convert clinical interest into sustained patient use.
Mexico Blood Glucose Monitoring Devices Market Trends and Insights
Rising Diabetes Burden and Undiagnosed Cases
Mexico’s diabetes burden creates durable demand for monitoring products across the Mexican blood glucose monitoring devices market. ENSANUT 2021-2024 reported Type 2 diabetes prevalence of 17.0%, while only 33.0% of diagnosed people achieved glycemic control below an HbA1c level of 7%. This pattern indicates that many people already receiving treatment may require more regular monitoring and clinical follow-up. The International Diabetes Federation estimated 5.6 million undiagnosed diabetes cases in Mexico in 2024, representing a sizable group that could enter care as screening improves. ENSANUT Continua 2023 found that 27.7% of eligible adults had been screened during the prior year, compared with a national target of 33.3%. The Mexican blood glucose monitoring devices market can therefore gain patients through both diagnosed disease management and higher screening coverage.Expanding Demand for Routine Home Monitoring
Routine monitoring at home remains important because diabetes treatment extends beyond clinic visits. The Federación Mexicana de Diabetes provides a self-monitoring manual for people with Type 1, Type 2, and gestational diabetes, reinforcing the role of home measurement in day-to-day disease management. Meters, strips, and lancets are familiar products for patients and clinicians, and they are more accessible than sensor-based systems. Their recurring use supports demand even when patients cannot afford continuous monitoring. The Mexican blood glucose monitoring devices market is also supported by public facilities that use these supplies in routine care. As more people receive a diagnosis, home testing can become a regular part of treatment rather than an occasional clinical procedure. This reinforces the need for reliable supply channels across both urban and non-metropolitan settings.High Out-of-Pocket Cost of CGM and Consumables
The cost of sensors and repeated replacement remains a persistent barrier to broader CGM use. CGM requires regular purchases rather than a one-time meter purchase, which can make continuous use difficult for households paying out of pocket. This constraint is especially relevant outside the upper-income segment and areas with limited private insurance. The Mexican blood glucose monitoring devices market can therefore show faster sensor growth in private channels than in the wider population. A PAHO review identified inequitable access to diabetes technology in Mexico, including differences between private centers and IMSS facilities. Cost also affects adherence because patients may interrupt monitoring when replacement products are not affordable. Manufacturers will need to balance premium features with pricing and channel arrangements that support continued use.Other drivers and restraints analyzed in the detailed report include:
- CGM Adoption in Private and Specialist Care
- Growing Digital Health and Connected Monitoring
- Limited Public Reimbursement for Continuous Monitoring
Segment Analysis
SMBG devices held 59.79% of 2025 revenue, giving conventional testing the largest position in the Mexican blood glucose monitoring devices market. Glucometers, test strips, and lancets are used across homecare, hospitals, and diagnostic settings. Their relative affordability supports broad access compared with sensor-based options. Test strips and lancets also generate recurring demand because they are used repeatedly. IMSS purchasing and clinical care pathways continue to support this established use of conventional supplies. Roche’s Accu-Chek portfolio is registered and marketed in Mexico, illustrating the established availability of meter-based products. The Mexican blood glucose monitoring devices market will continue to depend on this installed base through the forecast period.CGM devices are projected to expand at a 9.71% CAGR through 2031, faster than the conventional device category, supporting continued growth in mexico continuous glucose monitoring adoption. Abbott’s 2025 Mexican launch of FreeStyle Libre 2 Plus added real-time alarms and connected functionality to the local CGM offer. These features address needs that intermittent measurement cannot fully meet, especially for patients requiring closer glucose oversight. The category’s expansion is nevertheless limited by the cost of sensors and the absence of broad public reimbursement. CGM is likely to grow first through endocrinology practices and private pharmacies in large cities. The Mexico blood glucose monitoring devices market will thus combine a high-volume SMBG base with a smaller but faster-moving sensor category. Adoption will depend on whether suppliers can convert clinical interest into sustained patient use.
Complete Report Scope:
- By Device Type
- Self-Monitoring Blood Glucose Devices
- Glucometers
- Test Strips
- Lancets
- Continuous Glucose Monitoring Devices
- Sensors
- Durables
- Self-Monitoring Blood Glucose Devices
- By Patient Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- By End-user
- Hospitals & Clinics
- Homecare Settings
- Diagnostic Centers
- Specialty Diabetes Facilities
List of Companies Covered in this Report:
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- AgaMatrix
- Arkray
- Acon Laboratories
- Bionime
- Dexcom
- Eli Lilly and Company
- Roche
- Lifescan
- Medtronic
- Novo Nordisk
- Nipro
- Sinocare
- Senseonics
- Sanofi
- Trividia Health, Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- Agamatrix Inc.
- Arkray Inc.
- Acon Laboratories Inc.
- Bionime Corporation
- Dexcom Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- LifeScan
- Medtronic
- Novo Nordisk A/S
- Nipro Corporation
- Sinocare Inc.
- Senseonics Holdings, Inc.
- Sanofi
- Trividia Health, Inc.
